

**Committee on Energy and Commerce**  
**U.S. House of Representatives**  
Witness Disclosure Requirement - "Truth in Testimony"  
Required by House Rule XI, Clause 2(g)(5)

<b>1. Your Name:</b> Dr. Andrew Kolodny		
<b>2. Your Title</b> Director, Physicians for Responsible Opioid Prescribing (PROP)		
<b>3. The Entity(ies) You are Representing:</b> Physicians for Responsible Opioid Prescribing (PROP)		
<b>4. Are you testifying on behalf of the Federal, or a State or local government entity?</b>	<b>Yes</b>	<b>No</b> X
<b>5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.</b>  None		
<b>6. Please attach your curriculum vitae to your completed disclosure form.</b>		

**Signature:**  \_\_\_\_\_ **Date:** 2/27/2018

## **Andrew Kolodny, MD**



---

### **EDUCATION AND TRAINING**

**Columbia University College of Physicians and Surgeons**, New York, NY  
Fellowship in Public Psychiatry (2003-2004)

**Unites States Senate**, Washington, DC  
Daniel X Freedman Health Policy Fellowship (2003)

**Mount Sinai School of Medicine**, New York, NY  
Internship & Residency in Psychiatry (1999-2003)

**Temple University School of Medicine**, Philadelphia, PA  
M.D. (1995-1999)

**Queens College**, Flushing, NY  
B.A., Sociology (1989-1994)

---

### **LICENSURE AND BOARD CERTIFICATION**

New York State Medical License  
American Board of Psychiatry & Neurology  
American Board of Addiction Medicine

---

### **PRESENT POSITIONS**

**Brandeis University**, Heller School for Social Policy and Management, Waltham, MA  
Co-Director, Opioid Policy Research Collaborative (2016 – present)

**Physicians for Responsible Opioid Prescribing**  
Executive Director (2014 – present)  
President (2011 – 2014)

---

### **PAST POSITIONS**

**Phoenix House**, New York, NY  
Chief Medical Officer & Senior Vice President (2013-2016)

**Maimonides Medical Center**, Brooklyn, NY  
Chair, Department of Psychiatry (2008 – 2013)  
Vice Chair, Department of Psychiatry (2006 – 2008)

**New York City Department of Health and Mental Hygiene**, New York, NY  
Office of the Executive Deputy Commissioner  
Medical Director for Special Projects (2003-2005)

---

## **ACADEMIC APPOINTMENTS**

**New York University, Global Institute of Public Health**  
Research Professor

**Brandeis University, Heller School for Social Policy and Management**  
Senior Scientist

**Columbia University, Mailman School of Public Health**  
Adjunct Assistant Professor in Health Policy and Management

**Columbia University College of Physicians and Surgeons**  
Department of Psychiatry, Public Psychiatry Fellowship Program  
Voluntary Faculty

---

## **CONSULTING AND ADVISING**

National Judicial Opioid Task Force  
Pennsylvania Department of Aging  
CBS 60 Minutes: “The Whistleblower.” October 2017  
HBO Documentary: “Warning: This Drug May Kill You,” April 2017  
Last Week Tonight with John Oliver: Opioids, October 2016  
Massachusetts Hospital Association  
The National Governors Association  
The National Association of Attorneys General  
Office of Massachusetts Attorney General  
Office of Kentucky Attorney General  
New York State Interagency Task Force

---

## **AWARDS**

Dynamite Youth Center Foundation Annual Award  
Brooklyn Housing & Family Services Annual Award  
American Association of Psychiatric Administrators Annual Award  
NYC Department of Health and Mental Hygiene Outstanding Service Award

Mount Sinai School of Medicine Mildred Hope Witkin Award  
American Psychiatric Foundation Daniel X. Freedman Congressional Fellowship  
Mount Sinai School of Medicine Teacher of the Year  
City University of New York Jonas Salk Award  
Ford Foundation Diversity Initiative Award

---

## **GRANT SUPPORTED RESEARCH**

Principal Investigator, Utilization of the New York State Prescription Drug Monitoring Program to Reduce Risky Prescribing. Funded by the United States Food and Drug Administration

Principal Investigator, Treatment of Opioid Addicted Chronic Pain Patients with Buprenorphine. Funded by Maimonides Medical Center Research Foundation.

Co-investigator, Pilot Study of Buprenorphine Maintenance for Opioid Addicted Jail Inmates. Funded by National Institute on Drug Abuse.

Co-investigator, Substance Abuse, HIV, & Hepatitis Prevention for Minority Populations and Minority Reentry Populations in Communities of Color, funded by the Substance Abuse and Mental Health Services Administration.

---

## **JOURNAL PEER REVIEWS**

New England Journal of Medicine  
JAMA  
JAMA Internal Medicine  
Health Affairs  
Public Health Reports  
Journal of Public Health  
Drug and Alcohol Dependence  
American Journal of Public Health  
The American Journal on Addictions  
American Journal of Preventive Medicine  
Substance Abuse: Research and Treatment

---

## **PUBLICATIONS**

### *Academic Journals & Books*

1. Kolodny A, Frieden TF. Ten Steps the Federal Government Should Take Now to Reverse the Opioid Addiction Epidemic. JAMA. Epub 2017 Oct 12.
2. Lin D, Lucas E, Murimi IB, Kolodny A, Alexander GC. Potential Financial Conflicts of

Interest and Federal Opioid Guidelines: A Cross Sectional Study. *JAMA Intern Med.* 2017 Mar 1;177(3):427-428.

3. Kolodny A. Chronic Pain Patients Are Not Immune to Opioid Harms (letter). *J Pain Palliat Care Pharmacother.* 2016 Dec;30(4):330-331.
4. Hwang CS, Turner LW, Kruszewski SP, Kolodny A, Alexander GC. Primary Care Physicians' Knowledge and Attitudes Regarding Prescription Opioid Abuse and Diversion. *Clin J Pain.* 2016 Apr; 32(4):279-84.
5. Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, Alexander GC. The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction. *Annual Rev Public Health.* 2015 Mar 18;36:559-74.
6. Ballantyne JC, Kolodny A. Preventing prescription opioid abuse (letter). *JAMA.* 2015 Mar 10;313(10):1059.
7. Hwang CS, Turner LW, Kruszewski SP, Kolodny A, Alexander GC. Prescription Drug Abuse: A National Survey of Primary Care Physicians. *JAMA Intern Med.* 2015 Feb;175(2):302-4.
8. Kolodny A. Better late than never: time to up-schedule hydrocodone combination products. *Pain Medicine,* 2013;11:1627-1628.
9. Ballantyne J, Sullivan M, Kolodny A. Opioid Dependence vs Addiction—A Distinction Without a Difference? *Arch Intern Med.* 2012;172(17):1342-1343.
10. Von Korff M, Kolodny A, Deyo R, Chou R. Long-Term Opioid Therapy Reconsidered. *Annals of Internal Medicine.* 2011; 155:325-328.
11. Harrison M, Lednyak L, Kolodny A, Petit J. Buprenorphine: an office-based treatment for opioid dependence. *City Health Information.* 2008;27(4):25–32.
12. Magura S, Lee S, Salsitz E, Kolodny A, Whitley S, Taubes T, Seewald R, Joseph H, Kayman D, Fong C, Marsch L, Rosenblum A. Outcomes of Buprenorphine Maintenance in Office-based Practice. *Journal of Addictive Disorders.* 2007; 26(2):13-23.
13. Kolodny A. Psychiatrists as Administrators: The Perspective of a Mental Health Department Psychiatrist. *Psychiatric Quarterly.* 2007; April 14.
14. Kolodny A. Psychiatric consequences of methamphetamine use. *Journal of GLBT Psychotherapy.* 2006; 10:67-72.
15. Wainberg M, Kolodny A, Drescher J. Crystal meth and MSM: What mental health care professionals need to know. Binghamton, NY: Haworth Press, 2006.

16. Kolodny A, Sederer L. Brief interventions for alcohol problems. *City Health Information*. 2005; 24(8): 51-58. 2005.
17. Sederer LI, Kolodny AJ. Taking issue: Office based buprenorphine offers a second chance. *Psychiatric Services*. 2004; 55:743.
18. Sederer LI, Kolodny AJ. Detecting and treating depression in adults. *City Health Information*. 2004; 23(1):1-8.
19. Kolodny A, Lamon S, Sederer L. Buprenorphine: A new office-based treatment for opioid dependence. *City Health Information*. 2004; 23(4): 19-22.
20. Wainberg M, Kolodny A, Siever L. Personality Disorders. In: Preskorn SH, Feighner JP, Stanga CY & Ross R, eds., *Antidepressants: Past, Present and Future*. Springer Verlag, Berlin, Germany, 2004: 489-515.
21. American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (revision). *American Journal of Psychiatry* 159 (April Supplement):1-50, 2002. (Development and editing process).
22. Kolodny A, McVeigh T, Galea S. A neighborhood analysis of opiate overdose mortality in New York City and potential interventions: A discussion document, August 2003 (on file with the New York City Department of Health and Mental Hygiene).
23. American Psychiatric Association: Practice guideline for the assessment and treatment of patients with suicidal behaviors. *American Journal of Psychiatry* 160 (Nov. Supplement):1-60, 2003 (Development and editing process).
24. Min P, Kolodny A. The Middleman Minority Characteristics of Korean Immigrants in the United States. In: Kim K, ed. *Koreans in the Hood: Conflict with African Americans*. Baltimore: Johns Hopkins University Press, 1999: 131-154.

*Non-Academic*

1. Kolodny, A. "The Opioid Epidemic in 6 Charts." *The Conversation*. Oct 4, 2017.
2. Kolodny, A. "Trump is not off to a good start with opioid addiction." *The Hill*. April 25, 2017.
3. Kolodny, A. "Crooked Doctors Are Not Fueling the Opioid Epidemic." *New York Times*. Feb 17, 2016.
4. Kolodny, A. "Crush-Resistant Opioids: Not All They're Cracked Up to Be." *Media Planet*. Nov 8, 2015.

5. Kolodny A. “Naloxone: Necessary but Not Nearly Enough.” HuffPost. June 11, 2014.
6. Kolodny, A. “Zohydro: The FDA-Approved Prescription for Addiction.” HuffPost. Feb 26, 2014.
7. Kolodny, A. “Opioids Are Rarely the Answer.” New York Times. Feb 15, 2012.

---

## **SELECTED KEYNOTE PRESENTATIONS**

The Prescription Opioid and Heroin Crisis: Responding to an Epidemic of Addiction  
The American Association of Oral and Maxillofacial Surgeons Annual Conference  
San Francisco, CA, October 12, 2017.

The Prescription Opioid Addiction Crisis  
California Healthcare Foundation  
Oakland, CA, September 22, 2016.

The North American Opioid Addiction Epidemic  
International Medicine in Addiction Conference  
Melbourne, Australia, March 21, 2015.

The North American Opioid Addiction Epidemic  
World Health Organization  
Geneva, Switzerland, Nov 6, 2014.

Overview of the Opioid Analgesic Epidemic.  
National Governors’ Association Meeting  
Frankfort, Kentucky, January 15, 2013.

An Iatrogenic Epidemic—Lessons from the Opioid Experiment  
Seventh Annual Conference of The Addiction Institute of New York  
New York NY March 2, 2012.

The History of Heroin Treatment: from Methadone to Buprenorphine  
Bicentennial Celebration, New York City Department of Health and Mental Hygiene  
New York, NY, August 24, 2005.

---

## **SELECTED MEDIA APPEARANCES**

New York Times, Jan 17, 2016. “Drug Overdoses Propel Rise in Mortality Rates of Young Whites.”

C-SPAN Washington Journal, Oct 25, 2015. “Dr. Andrew Kolodny on Combating Drug Abuse.”

New York Times, Oct 22, 2015. “Obama Strikes Personal Note as He Urges Help for Addiction.”

New York Times, Oct 8, 2015. “F.D.A. Approval of OxyContin Use for Children Continues to Draw Scrutiny.”

NPR On Point with Tom Ashbrook, Oct 6, 2015. “American Opioid Addiction Keeps Growing.”

Wall Street Journal, April 1, 2015. “FDA Offers Guidance on Developing Opioids Less Prone to Be Abused.”

Forbes, Feb 6, 2015. “How Obama Plans To Combat Prescription Opioid And Heroin Abuse In 2016.”

PBS NewsHour, Jan 6, 2015. “How Should the U.S. Regulate Powerful Painkillers? Boston Globe. Dec 29, 2014.

Groups unite against curbing painkillers USA Today, Dec 15, 2014. Doctors prescribing most potent painkillers face scrutiny.”

New York Times, Nov 20, 2014. “FDA Approves Hysingla, a Powerful Painkiller.”

Wall Street Journal, Oct 1, 2014. “Maker of Painkiller Tries to Curb Abuse.”

Washington Post, Sept 28, 2014. “Overdose deaths spur families to march on Mall over opioid epidemic.”

New York Times, Aug 28, 2014. Heroin’s Death Toll Rising in New York, Amid a Shift in Who Uses It

LA Times, Jul 25, 2014. FDA approves new opioid pain reliever designed to be hard to abuse

Wall Street Journal, Jan 25, 2013. FDA Panel Calls for New Curbs on Common Painkiller

Washington Post, Dec 30, 2012. “Rising Painkiller Addiction Shows Damage from Drugmakers’ Role in Shaping Medical Opinion.”